R&D

News

Astellas gains three cancer drugs with $405m Potenza buy

Astellas has taken an option to acquire US biotech Potenza Therapeutics after the companies spent more than three years working together on cancer immunotherapies.

News

Illustration of a nerve cell on a colored background with light effects

Neurocrine slumps as Tourette's drug fails clinical trial

Shares in Neurocrine Biosciences slumped by as much as a fifth after a much-anticipated trial in Tourette’s syndrome missed the mark.

News

Axovant axes neuroscience drug, focuses on gene therapies

Swiss biotech Axovant started the year badly, dropping its Alzheimer’s drug intepirdine after it failed in a trial, and it has ended with another flop from a neuroscience drug, nelotanserin

News

Closeup of X-ray photography of human brain

Certain brain tumours could respond to immunotherapy

Some brain tumours may respond to immunotherapy after all, according to a new study.

News

Merck KGaA links with AI firm to iron out side-effects durin...

Germany’s Merck KGaA has begun a licensing agreement with Canadian pharma R&D company Cyclica using artificial intelligence (AI) to uncover new drug targets and predict any side effects

Views & Analysis